Skip to main content
. 2019 May 21;10(10):2288–2298. doi: 10.7150/jca.30680

Figure 4.

Figure 4

A diagram showing a potential mechanism how non-BZDs such as zopiclone or zaleplon contribute to increased risk of subsequent cancers. The number refers to the corresponding supporting reference.